373 related articles for article (PubMed ID: 24309019)
1. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
Shapiro AB; Austin CA
Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
[TBL] [Abstract][Full Text] [Related]
2. A high-throughput-compatible, fluorescence anisotropy-based assay for ATP-dependent supercoiled DNA relaxation by human topoisomerase IIα.
Shapiro AB
Biochem Pharmacol; 2013 May; 85(9):1269-77. PubMed ID: 23415903
[TBL] [Abstract][Full Text] [Related]
3. High-yield production and characterization of biologically active GST-tagged human topoisomerase IIα protein in insect cells for the development of a high-throughput assay.
Singh PK; Chan PF; Hibbs MJ; Vazquez MJ; Segura DC; Thomas DA; Theobald AJ; Gallagher KT; Hassan NJ
Protein Expr Purif; 2011 Apr; 76(2):165-72. PubMed ID: 20709174
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
5. A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay.
Shapiro A; Jahic H; Prasad S; Ehmann D; Thresher J; Gao N; Hajec L
J Biomol Screen; 2010 Oct; 15(9):1088-98. PubMed ID: 20930214
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
7. Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks.
McClendon AK; Rodriguez AC; Osheroff N
J Biol Chem; 2005 Nov; 280(47):39337-45. PubMed ID: 16188892
[TBL] [Abstract][Full Text] [Related]
8. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ.
Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE
Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
10. Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.
McClendon AK; Gentry AC; Dickey JS; Brinch M; Bendsen S; Andersen AH; Osheroff N
Biochemistry; 2008 Dec; 47(50):13169-78. PubMed ID: 19053267
[TBL] [Abstract][Full Text] [Related]
11. An atypical type II topoisomerase from Mycobacterium smegmatis with positive supercoiling activity.
Jain P; Nagaraja V
Mol Microbiol; 2005 Dec; 58(5):1392-405. PubMed ID: 16313624
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
13. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.
Gilroy KL; Leontiou C; Padget K; Lakey JH; Austin CA
Nucleic Acids Res; 2006; 34(5):1597-607. PubMed ID: 16549872
[TBL] [Abstract][Full Text] [Related]
14. [DNA supercoiling and topoisomerases in Escherichia coli].
Gómez-Eichelmann MC; Camacho-Carranza R
Rev Latinoam Microbiol; 1995; 37(3):291-304. PubMed ID: 8850348
[TBL] [Abstract][Full Text] [Related]
15. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
Andrea JE; Adachi K; Morgan AR
Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
[TBL] [Abstract][Full Text] [Related]
16. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
[TBL] [Abstract][Full Text] [Related]
17. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
McClendon AK; Osheroff N
Biochemistry; 2006 Mar; 45(9):3040-50. PubMed ID: 16503659
[TBL] [Abstract][Full Text] [Related]
18. The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.
Gilroy KL; Austin CA
PLoS One; 2011 Feb; 6(2):e14693. PubMed ID: 21358820
[TBL] [Abstract][Full Text] [Related]
19. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
20. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]